Brokerages Anticipate Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share

Equities analysts expect that Horizon Pharma PLC (NASDAQ:HZNP) will post earnings per share (EPS) of $0.22 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Horizon Pharma PLC’s earnings, with the lowest EPS estimate coming in at $0.19 and the highest estimate coming in at $0.25. Horizon Pharma PLC posted earnings per share of $0.66 in the same quarter last year, which suggests a negative year over year growth rate of 66.7%. The company is scheduled to issue its next earnings results on Monday, February 26th.

On average, analysts expect that Horizon Pharma PLC will report full year earnings of $1.10 per share for the current year, with EPS estimates ranging from $1.05 to $1.14. For the next year, analysts expect that the firm will report earnings of $1.28 per share, with EPS estimates ranging from $1.04 to $1.40. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Horizon Pharma PLC.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.04. Horizon Pharma PLC had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. During the same quarter last year, the business earned $0.70 earnings per share. Horizon Pharma PLC’s revenue was up 30.1% compared to the same quarter last year.

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $17.00 price target (up previously from $13.00) on shares of Horizon Pharma PLC in a research note on Wednesday, August 9th. Zacks Investment Research raised shares of Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. BMO Capital Markets reaffirmed a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a report on Friday, July 28th. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, BidaskClub lowered shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Horizon Pharma PLC has an average rating of “Buy” and a consensus target price of $18.42.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2017/11/13/brokerages-anticipate-horizon-pharma-plc-hznp-to-announce-0-22-earnings-per-share.html.

A number of large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in Horizon Pharma PLC by 18.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock worth $94,254,000 after acquiring an additional 1,167,722 shares during the last quarter. Brown Advisory Inc. bought a new position in shares of Horizon Pharma PLC in the 3rd quarter valued at about $145,000. Greenwoods Asset Management Ltd boosted its stake in shares of Horizon Pharma PLC by 69.2% in the 3rd quarter. Greenwoods Asset Management Ltd now owns 220,000 shares of the biopharmaceutical company’s stock valued at $2,790,000 after purchasing an additional 90,000 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Horizon Pharma PLC by 24.8% in the 3rd quarter. Wells Fargo & Company MN now owns 456,169 shares of the biopharmaceutical company’s stock valued at $5,784,000 after purchasing an additional 90,692 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Horizon Pharma PLC by 12.9% in the 3rd quarter. Legal & General Group Plc now owns 63,843 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 7,291 shares during the last quarter. 83.80% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Horizon Pharma PLC (NASDAQ HZNP) traded up $0.32 during midday trading on Monday, reaching $13.57. 2,833,700 shares of the company were exchanged, compared to its average volume of 3,526,486. Horizon Pharma PLC has a 1 year low of $9.45 and a 1 year high of $21.98. The firm has a market capitalization of $2,210.00, a price-to-earnings ratio of 9.83, a P/E/G ratio of 1.15 and a beta of 1.32. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma PLC (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply